Exelixis Slashes Staff Again, Focuses All Internal Development on XL184
This article was originally published in The Pink Sheet Daily
Executive Summary
As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.
You may also be interested in...
Panel: Oncology Business Models Determined By Capital And Culture
Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.
Solution Development: A Model For Structuring Biotechs And Developing Better Drugs
The biopharma industry must think differently about funding high-risk/reward development of drug candidates against novel targets. Multiplexing Phase II proof-of-concept trials can light a path toward lower-risk pivotal studies and provide a model for building biotechs to deliver what patients, providers, payors, and investors all want: solutions.
Oncology Start-up Cyterix Pharmaceuticals Launches With $9.2MM From VCs
Two venture firms bet on the Scottish university spin-out, now based California, as it develops pro-drugs activated by a specific enzyme family.